Compare Sana Biotechnology Inc (SANA) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Wells Fargo & Co — how do they compare? Sana Biotechnology Inc trades at $2.85 (market cap $836.71M), while Wells Fargo & Co trades at $83.53 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 296.5× Sana Biotechnology Inc's market cap, and Wells Fargo & Co pays a 2.44% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Wells Fargo & Co for 87 Days on average.
| SANA | WFC | |
|---|---|---|
Market Cap | $836.71M | $248.06B |
Volume | 4,507,444 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $5.92 | $96.40 |
52-Week Low | $2.68 | $73.42 |
Typical Hold Time | 23 Days | 87 Days |
Enterprise Value | $749.96M | $503.91B |
Dividend Yield | — | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Wells Fargo (WFC) trades at $83.16, up 3.61% today, showing resilience amid a bearish technical signal. The stock benefits from strong profitability with a 25.97% net margin and a modest P/E of 11.92, indicating potential undervaluation relative to earnings. Recent positive developments include a credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01) and a renewed mortgage servicing agreement with Intercontinental Exchange (Business Wire, 2026-09-29).
The outlook is cautiously optimistic, supported by analyst consensus targets near $99.13 and improving net interest income prospects from Fed rate hikes. Key risks include volatile cash flows, with 2025 operating cash flow negative $19.0B, and execution challenges amid leadership transitions like the chief risk officer's retirement (Reuters, 2026-09-23).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
